This reality also could impact stock performance. That said, even with positive results in a relatively small sample size, there is no guarantee that Pfizer’s vaccine will be approved or will work on a wide-scale. Conversely, work-from-home stocks like Peloton could suffer as more people may opt to exercise in a gym, rather than inside their home. Here are some other sectors to watch for:Įssentially, any business that could thrive when in-person activity increases is a potential winner in this scenario. In April 2019, Zoom announced its IPO priced at. Think of it this way: Zoom is the poster child of the work from home movement. Other stocks outside the healthcare sector could benefit with the approval of a potential vaccine. Zoom Video Communications Inc ZM -1.18 + Free Alerts shares are trading lower in possible reaction to positive data from Pfizer for its COVID-19 oral antiviral treatment candidate, which has. Zoom has been the go-to platform globally for the remote workforce. ![]() And a couple of red flags to me from this earnings call last night to me, Julie, looking for their. While a 20% stock price drop is relatively small against the backdrop of year-to-date performance, it could be a sign of further downward pressure on Zoom’s share price if the vaccine receives regulatory and marketing approval. We have seen from Zoom throughout the year, the stock I believe is down close to 30 on the year. If more people return to in-person work or if social distancing rules are eased, or both, fewer people could use Zoom. A potential vaccine, if effective and if widely distributed, implies that Zoom’s growth and user base could slow. Zoom investors saw the potential for continued hypergrowth fade out because there will be lower demand for Zoom calls when life gets back to normal again.
0 Comments
Leave a Reply. |